Search Bar & Filters
Found 23 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.
Actively Recruiting
Researchers are evaluating how well guselkumab works to improve symptoms of psoriatic arthritis, an inflammatory joint disease affecting people with psoriasis, which causes red, scaly skin patches. This observational study uses musculoskeletal ultrasound MSUS to assess disease activity and treatment effects in a real-world setting, focusing on participants with active psoriatic arthritis. Participants with confirmed psoriatic arthritis who are treated with guselkumab according to standard clinical practice are enrolled. No study drug is provided instead, data from routine clinical care, including ultrasound results, are collected. Participants will also answer questions about their health and well-being. The study tracks outcomes such as reductions in synovitis scores, disease activity indices, enthesitis resolution, pain scores, and treatment persistence over periods extending up to 52 weeks. During the study, participants undergo assessments at baseline and at weeks 12, 24, and 52, including ultrasound examinations and clinical evaluations. Researchers measure outcomes like global synovitis scores, disease activity, minimal disease activity achievement, and adverse events. Data collection aligns with routine care visits, allowing long-term monitoring of treatment effects and safety. The study is sponsored by Janssen Research & Development, LLC and runs from December 2025 until June 2028.
Actively Recruiting
Researchers are conducting a non-interventional, retrospective observational study to better understand the diagnosis and treatment of patients with early-stage and locally advanced non-small cell lung cancer NSCLC, specifically stages I to III. The study addresses the variability in treatment approaches, as there is no clear consensus on the best timing, sequence, or combination of surgery, chemotherapy, and radiotherapy for these patients. This research aims to collect real-world data to improve knowledge on how these patients are managed across different healthcare settings. This study involves reviewing past medical records of patients diagnosed with stage I-III NSCLC who underwent curative surgery or radiotherapy between January 2018 and June 2019. The data collection covers treatment approaches, discussions in multidisciplinary teams, healthcare resource use, and direct medical costs from January 2018 to January 2021. There are no interventions or treatments being given directly as part of this study since it is observational and retrospective. Participants involvement consists of allowing access to their medical charts and treatment records for data capture. Researchers will evaluate treatment timelines and approaches as they occurred in routine clinical practice. The study also tracks the extent of healthcare resources used and costs involved. Data privacy is maintained by obtaining informed consent from patients or their representatives. The study is expected to conclude in June 2025.
Actively Recruiting
This research evaluates whether adding axitinib to nivolumab maintenance treatment after initial therapy with nivolumab plus ipilimumab can improve response rates in patients with metastatic renal cell carcinoma mRCC who have not achieved a complete response or experienced disease progression. The study is a phase II, open-label trial that aims to increase partial response rates based on prior trial results. Participants are randomly assigned to one of two groups one group receives axitinib 5 mg twice daily orally in addition to nivolumab 480 mg intravenously every four weeks, while the other group continues with nivolumab alone at the same dose and schedule. Treatment continues until disease progression, unacceptable side effects, patient withdrawal, or physician decision. The trial plans to enroll 118 patients to detect meaningful differences between groups. Throughout the study, participants will be closely monitored with tumor assessments and health evaluations to measure outcomes such as progression-free survival, overall survival, depth and duration of response, and treatment-related adverse events. Follow-up includes tracking health status and life status from enrollment through treatment and up to 100 days after the last dose. The study is sponsored by Consorzio Oncotech and started in April 2023, with an estimated end date in April 2027.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
Researchers are studying patients with early breast cancer, focusing on those with HER2-positive and Triple Negative tumors who have received neoadjuvant treatment in the past five years. The study aims to understand the percentage of such patients among all who underwent neoadjuvant treatment, along with analyzing treatment choices, tumor characteristics, responses to therapy, surgical procedures, and survival outcomes based on molecular subtypes and initial cancer staging. This observational study reviews clinical data collected from multiple oncology centers in Italy. It examines neoadjuvant treatments given before surgery, the radiological responses assessed by breast MRI, ultrasound, or mammography, and the surgical methods used on the breast and axilla. The study also looks at adjuvant therapies after surgery and tracks changes in eligibility criteria for neoadjuvant treatments over the last five years. Participants medical records will be evaluated to capture information on tumor pathology, treatment responses, and survival rates including disease-free and overall survival. The primary measurement is the percentage of HER2-positive and Triple Negative patients treated neoadjuvantly during the defined period. Secondary analyses include treatment patterns, pathological and radiological responses, surgical details, and correlations between complete pathological response and survival outcomes. The study spans five years of retrospective data and is led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Actively Recruiting
This research aims to evaluate financial toxicity FT in patients undergoing radiotherapy for various cancer types in Italy. Financial toxicity refers to the financial burden and distress patients may experience during cancer treatment. The study is observational and multicenter, focusing on assessing FT using the PROFFIT questionnaire, a validated tool designed specifically for Italian cancer patients. Researchers will also explore how changes in financial toxicity relate to quality of life, treatment side effects, and overall survival. Participants will complete the PROFFIT questionnaire, which consists of 16 items measuring financial toxicity and its possible causes. The questionnaire will be administered before starting radiotherapy, at the end of radiotherapy treatment, and during the first follow-up visit 1 to 2 months after treatment. Additional assessments include the EORTC QLQ-C30 questionnaire to measure quality of life and the PRO-CTCAE to evaluate treatment-related symptoms. The study compares financial toxicity across different groups based on cancer type, radiotherapy type, treatment, age, and sex. During the study, patients will be asked to complete questionnaires at specific time points baseline, end of radiotherapy, and first follow-up visit within 1 to 2 months post-treatment, with follow-up up to 12 months. Researchers will monitor financial toxicity scores and analyze how these relate to patients quality of life and treatment effects. Participation involves completing surveys and clinical monitoring without any experimental treatment. The study duration varies depending on individual follow-up schedules.
Actively Recruiting
Researchers are assessing the risks of blood clots ischemic events and bleeding after transcatheter aortic valve replacement TAVR in patients with severe aortic stenosis. This study focuses on how different antithrombotic therapies and surgical risk levels affect these risks. It also explores how the type of valve prosthesis and blood count factors like hemoglobin and platelets influence daily ischemic and bleeding risks over time. The aim is to improve personalized treatment strategies after TAVR. Participants will be grouped based on their surgical risk low, intermediate, or high and the antithrombotic therapy they receive, such as single or dual antiplatelet therapy, oral anticoagulation, or combinations. The study observes changes in antithrombotic treatments at 1 month, 90 days, and 1 year following TAVR. It also examines the impact of prosthesis characteristics and blood abnormalities on risk events using repeated-event analysis. During the study, participants ischemic and bleeding risks will be tracked at 30 days, 90 days, and 1 year after the procedure. Researchers will monitor therapy adjustments, the timing and type of changes, and collect data on anemia and low platelet counts. The study evaluates these outcomes to understand how risks fluctuate over time and how personalized antithrombotic strategies might better manage patients after TAVR.
Actively Recruiting
Researchers are conducting the RICMAF Study, an observational, multicenter, non-drug study in Italy focused on Anderson-Fabry Disease AFD, a rare genetic disorder that affects multiple organs, especially the heart. The study aims to better understand AFDs clinical course, its cardiac complications, and the relationship between genetic mutations and disease progression. This research seeks to improve patient care by identifying early markers of heart involvement and predicting cardiovascular problems. The study collects data from patients diagnosed with AFD according to international guidelines, starting from January 1, 1981, through December 31, 2031. It includes both retrospective and prospective phases, gathering comprehensive clinical, genetic, laboratory, and imaging information through a national patient registry. Patients undergo regular assessments as part of their standard care, including cardiology evaluations, ECG, echocardiography, and cardiac MRI when appropriate. Participants contribute data during routine clinical visits without additional study-specific procedures. The research team collects information from medical records and follow-up visits, including family history, symptoms, genetic tests, and heart monitoring results. The primary outcome is to define the natural history of Fabry disease over an average follow-up of five years, while secondary outcomes focus on cardiac risk stratification, genotype correlations, and early diagnostic biomarkers. The study duration extends up to 10 years, with ongoing data analysis and publication of findings.
Actively Recruiting
Researchers are investigating lung frailty and barotrauma in patients with Acute Respiratory Distress Syndrome ARDS, including those with COVID-19 and non-COVID-19 causes. Barotrauma is a common and serious complication in ARDS that can occur even in patients breathing spontaneously. The study aims to confirm the predictive value of a radiological sign called the Macklin effect, assess inflammatory markers, and develop a management algorithm for patients with this vulnerable lung condition. The study involves reviewing chest CT scans and analyzing blood and bronchoalveolar lavage fluid from ARDS patients to measure multiple inflammatory biomarkers. These include various interleukins, interferon, angiopoietin, tumor necrosis factor receptors, and proteins linked to lung injury and inflammation. The research includes a retrospective analysis of imaging and a prospective collection of samples and clinical data to identify lung frailty features and support personalized care strategies. Participants will undergo standard chest CT scans during their hospital stay and provide blood and bronchoalveolar lavage samples within 12 hours after intubation. Researchers will monitor barotrauma development over 30 days or until hospital discharge using imaging and clinical records. The study will analyze patient outcomes and biomarker profiles to better understand lung injury risks, aiming to improve early risk detection and tailor treatments for ARDS patients.
1-10 of 23
1